TET2 mutations are frequent in TFH-derived lymphomas, but how epigenetic disruption initiates malignant T cell transformation is unclear. We generated Cd4cre;Tet2FL/FL mice, which developed aggressive T cell lymphoma (m-TCL) with a TFH cell–like immunophenotype. Genome-wide transcriptomics and epigenetic profiling of Tet2−/− CD4+ T cells prior to lymphoma development showed hyperactive TCR, PI3K signaling, and dysregulated TH differentiation program, with proliferation promoting signal transduction at the lymphoma stage. Tet2 loss promoted hyperplasticity under in vitro conditions but favored conditional TFH differentiation. Reduced 5-hmC levels at regulatory genomic elements, resulted in transcriptional rewiring of TFH-associated genes, promoting ICOS(L)-mediated PI3K signaling. TET2-KO human CD4+ T cells showed conserved epigenetic changes with increased proliferation, decreased exhaustion, increased memory marker expression, and clonal expansion with restricted TCR repertoire under in vitro conditions. scRNA-seq revealed a persistent proliferative cluster characterized by elevated stem-like transcriptional features compared with WT counterparts. Tet2−/− m-TCLs allografted into NSG mice showed a significant response to epigenetic (5-azacytidine) and PI3K inhibitors (duvelisib) alone or in combination.
Tet2 deficiency alters CD4+ T cell function and promotes T cell lymphoma with a TFH cell immunophenotype
T.B. Heavican-Foral, Y. Li, W. Lone, and A. Bouska contributed equally to this paper.
Disclosures: J. Robinson is a current employee for the commercial company ViiV Healthcare. At the time of his involvement in this publication, he was not an employee of ViiV Healthcare. His current work at ViiV Healthcare is unrelated to the work described in this publication. A. Rao reported grants from NIH during the conduct of the study and personal fees from Biomodal outside the submitted work; in addition, A. Rao had a patent on TET proteins licensed (Biomodal) and was a scientific advisory board member for Biomodal. No other disclosures were reported.
- Award Id(s): UH2/3 CA206127-02,R41CA221466-01A1,P01CA229100,P30CA033572
- Award Id(s): TRP-6129-04,R01CA251412,R01CA244900
Tayla B. Heavican-Foral, Yuping Li, Waseem Lone, Alyssa Bouska, Jibin Zhang, Ruimeng Yang, Xuxiang Liu, Ab Rauf Shah, Abdul Rouf Mir, Joseph Rohr, Dylan Jochum, Anurag Kumar, Ravneet Singh Chawla, Catalina Amador, Jiayu Yu, Tyler Herek, Jacob Robinson, Chengfeng Bi, Sunandini Sharma, Tyler Gilbreath, R. Katherine Hyde, Timothy W. McKeithan, Chan-Wang Lio, Anjana Rao, Giorgio Inghirami, Joesph Khoury, Wing C. Chan, Javeed Iqbal; Tet2 deficiency alters CD4+ T cell function and promotes T cell lymphoma with a TFH cell immunophenotype. J Exp Med 1 June 2026; 223 (6): e20250194. doi: https://doi.org/10.1084/jem.20250194
Download citation file:
Sign in
Email alerts
Advertisement
